Akin Advises Pharmakon Advisors in $500 Million Senior Secured Term Loan to Mineralys Therapeutics

Contact:
(New York) – Akin advised Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry, and the BioPharma Credit funds, in connection with an up to $500 million senior secured term loan to Mineralys Therapeutics, Inc., with the first tranche of $100 million funded at closing. Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone.
The Akin team was led by tax partner Geoffrey Secol and included fellow tax partners Stuart Leblang and David Snyder and associate John Kwack; international trade partner Nnedinma Ifudu Nweke; health care & life sciences partner Nate Brown and associate Jenna Becker; and corporate associates Jake Gawlak and Yossi Abadi.
For additional information on the transaction, please click here.
Akin is a leading international law firm with more than 1,000 lawyers in offices throughout the United States, Europe, Asia and the Middle East.
# # #








